Immunome Ahead of a Binary Runway: Tactical Long on IMNM With Defined Risk
Immunome (IMNM) is a clinical-stage antibody developer trading at a $2.4B+ market cap despite negative earnings and a large negative free cash flow. If the market is right about an upcoming NDA-related run, shares have room to move toward the analyst consensus near $30. This trade pairs a tactical long entry at $22.00 with a $30.00 target and tight…